Brief: Tiziana Life Sciences Announces Positive Six-Month Clinical Results In Multiple Sclerosis Patients Treated With Intranasal Foralumab
16/10/2023 12:11
Oct 16 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES POSITIVE SIX-MONTH
CLINICAL
RESULTS IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH INTRANASAL
FORALUMAB
Source text for Eikon: ID:nGNXgz9rY
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis